Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Hosted on MSN21h
Don't wait for a holiday surge. Now is a good time to get your flu and COVID-19 vaccines
The Pfizer and Moderna shots are formulated against a virus subtype called KP.2 while the Novavax vaccine targets its parent ...
Medpage Today on MSN1d
Zepbound's Weight Loss, Cardiometabolic Benefits Hold Up at 3 Years
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new ...
Pfizer: Discounted For A Reason - But Dividend Story Remains Rich
Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...
Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
BioSpace1h
Pfizer Makes $1B Commitment in China to Boost Innovation, Target Chinese Market
The five-year investment will go toward the construction of a new R&D facility in Beijing to develop innovative therapies and integrate the world’s second most populated country in the company’s ...
FiercePharma6h
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
FiercePharma1d
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
The Motley Fool on MSN4d
Is Pfizer Stock a Bargain for Long-Term Investors?
Pfizer's 14% operational growth in non-COVID products shows the core business is stronger than many believe. The company's ...
Zacks.com on MSN3d
Buy, Sell or Hold Pfizer Stock After Q3 Earnings Beat, Guidance Boost?
On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...
3 Reasons Pfizer Looks Like a No-Brainer Buy Right Now
Pfizer's diverse operations put it in an excellent position to grow in the long run. It doesn't have a top weight loss treatment on the market, but that could change. Its above-average dividend yield ...
2 Healthcare Dividend Stocks That Are Screaming Buys in November
One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...